Podcast: Play in new window | Download (Duration: 37:28 — 34.3MB) | Embed
Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | iHeartRadio | Blubrry | Podcast Index | TuneIn | Deezer | RSS | More
HOST: Hildy Grossman, CO-HOST: Jordan Rich
GUEST: Zofia Piotrowska, MD, MHS, Massachusetts General Hospital
This podcast delves deeper into the evolving understanding of the HER2 biomarker in lung cancer, twenty years after its discovery. We’re joined by Dr. Zofia Piotrowska, renowned oncologist and researcher at Massachusetts General Hospital, to build on our previous discussion, “HER2 Isn’t Just About Her!” Dr. Piotrowska explores the intricate nuances of HER2 in lung cancer, explaining how subtle genetic variations can significantly impact treatment outcomes. While HER2 biomarkers are more frequently observed in non-smokers, women, and younger patients, it’s crucial to remember that anyone with lungs can develop lung cancer. Of critical importance in diagnosis and treatment decisions is comprehensive biomarker testing. This valuable information empowers clinicians to tailor treatment plans with precision. This episode highlights the remarkable progress made in precision medicine in combating HER2-positive lung cancer, offering renewed hope for patients, their loved ones, and the entire medical community.